Correlation Between EPIRUS Biopharmaceutica and NovAccess Global

Can any of the company-specific risk be diversified away by investing in both EPIRUS Biopharmaceutica and NovAccess Global at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining EPIRUS Biopharmaceutica and NovAccess Global into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between EPIRUS Biopharmaceuticals and NovAccess Global, you can compare the effects of market volatilities on EPIRUS Biopharmaceutica and NovAccess Global and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in EPIRUS Biopharmaceutica with a short position of NovAccess Global. Check out your portfolio center. Please also check ongoing floating volatility patterns of EPIRUS Biopharmaceutica and NovAccess Global.

Diversification Opportunities for EPIRUS Biopharmaceutica and NovAccess Global

0.0

Correlation Coefficient

EPIRUS Biopharmaceutica  NovAccess Global

Pay attention - limited upside

The 3 months correlation between EPIRUS and NovAccess is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding EPIRUS Biopharmaceuticals and NovAccess Global in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NovAccess Global and EPIRUS Biopharmaceutica is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on EPIRUS Biopharmaceuticals are associated (or correlated) with NovAccess Global. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NovAccess Global has no effect on the direction of EPIRUS Biopharmaceutica i.e., EPIRUS Biopharmaceutica and NovAccess Global go up and down completely randomly.

Pair Corralation between EPIRUS Biopharmaceutica and NovAccess Global

If you would invest  1.40  in NovAccess Global on September 13, 2024 and sell it today you would lose (0.50) from holding NovAccess Global or give up 35.71% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	1.56%
Values	Daily Returns

EPIRUS Biopharmaceuticals  vs.  NovAccess Global

EPIRUS Biopharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days EPIRUS Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, EPIRUS Biopharmaceutica is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

NovAccess Global

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in NovAccess Global are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, NovAccess Global showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with EPIRUS Biopharmaceutica and NovAccess Global

The main advantage of trading using opposite EPIRUS Biopharmaceutica and NovAccess Global positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if EPIRUS Biopharmaceutica position performs unexpectedly, NovAccess Global can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NovAccess Global will offset losses from the drop in NovAccess Global's long position.

The idea behind EPIRUS Biopharmaceuticals and NovAccess Global pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..